Daxor Corporation Initiates Strategic Collaboration with CHF Solutions, Inc. to Manage Patients with Fluid Overload
November 01 2018 - 8:30AM
DAXOR CORPORATION (
NYSE MKT:
DXR) announced today that it has entered into an agreement
with CHF Solutions (Nasdaq: CHFS) to explore clinical synergies
between the company’s BVA-100 Blood Volume Analyzer and CHF
Solutions’ Aquadex FlexFlow® System to assess the benefit of
combining Daxor’s fluid volume diagnostic with Aquadex FlexFlow
therapy for the management of the fluid overloaded patient.
“Daxor serves the same community of health care
providers seeking to improve heart failure outcomes. We feel that
the combination of our precision diagnostic, which is the most
direct and objective clinical measure of volume overload, combined
with CHF Solutions’ therapy for effective and predictable volume
removal holds the potential for significantly improved results for
patients treated with this unique combination,” commented Michael
Feldschuh, CEO of Daxor Corporation. “We further believe that this
relationship has tremendous potential to not only benefit patients,
but to improve hospital outcomes and provide both companies with
opportunities to demonstrate synergies to their customers. We look
forward to exploring the many benefits of working with CHF
Solutions.”
The collaboration will initiate with an
evaluation of the benefits of blood volume measurement in helping
to determine ultrafiltration management with CHFS’s Aquadex
FlexFlow system in a pilot study. Recently published outcomes of
245 heart failure admissions showed a decrease in heart failure
mortality of 86 percent and 30-day readmissions of 56 percent when
the BVA-100 diagnostic was used to guide treatment. A subset of
those data included treatment using the Aquadex FlexFlow system to
reduce fluid overload. The pilot study is intended to provide
additional insight on the potential benefit of using the devices in
tandem to enhance clinical outcomes.
“There is proven clinical evidence demonstrating
that aquapheresis is an effective means of managing fluid
overloaded patients who have failed diuretics,” said John Erb,
chairman and CEO of CHF Solutions. “We believe that working with
Daxor to maximize effective fluid management with the Aquadex
FlexFlow systemis of important benefit to patient care as well as
our business strategy.”
About Daxor Corporation
Daxor Corporation is an innovative medical
instrumentation and biotechnology company. The company manufactures
the BVA-100 Blood Volume Analyzer, the first instrument approved by
the FDA to provide rapid direct measurement of a patient’s blood
volume. Daxor believes that the BVA-100 Blood Volume Analyzer has
the potential to transform therapy in a broad range of surgical and
medical conditions. It is the company’s goal, working in
conjunction with hospitals and clinics, to achieve that
possibility. Ultimately, its mission is to help hospitals and
physicians incorporate Daxor’s BVA-100 diagnostic to significantly
improve the quality of patient care. For more information please
visit Daxor’s website at http://www.daxor.com.
About CHF Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is a
medical device company focused on commercializing the Aquadex
FlexFlow system for aquapheresis therapy. The Aquadex FlexFlow
system is indicated for temporary (up to eight hours)
ultrafiltration treatment of patients with fluid overload who have
failed diuretic therapy and extended (longer than 8 hours)
ultrafiltration treatment of patients with fluid overload who have
failed diuretic therapy and require hospitalization. All treatments
must be administered by a healthcare provider, under physician
prescription, both of whom having received training in
extracorporeal therapies. The company's mission is to predict,
measure, and control patient fluid balance through science,
collaboration, and innovative medical technology. CHF
Solutions is a Delaware corporation headquartered
in Minneapolis, Minnesota with wholly owned subsidiaries
in Australia and Ireland. The company has been
listed on the NASDAQ Capital Market since February 2012.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact Information:
Daxor Corporation: Soren Thompson Investor Relations212-330-8502
sthompson@daxor.com
Investor Relations Contact:Bret ShapiroSr. Managing PartnerCORE
IR561-479-8566brets@coreir.com
Media Contact:Jules AbrahamCORE
IR917-885-7378juleas@coreir.com
Daxor (AMEX:DXR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Daxor (AMEX:DXR)
Historical Stock Chart
From Apr 2023 to Apr 2024